Real-World Clinical Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide （BIC/FTC/TAF） Single-Tablet Regimen

Fen TENG; Bo TIAN; Chongxi LI; Yongmei JIN; Haiyun CHEN; Jun LIU

doi:10.12259/j.issn.2095-610X.S20240411

Volume 45 Issue 4

Apr. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(4): 74-80

Fen TENG, Bo TIAN, Chongxi LI, Yongmei JIN, Haiyun CHEN, Jun LIU. Real-World Clinical Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide （BIC/FTC/TAF） Single-Tablet Regimen[J]. Journal of Kunming Medical University, 2024, 45(4): 74-80. doi: 10.12259/j.issn.2095-610X.S20240411

Citation:

Fen TENG, Bo TIAN, Chongxi LI, Yongmei JIN, Haiyun CHEN, Jun LIU. Real-World Clinical Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide （BIC/FTC/TAF） Single-Tablet Regimen[J]. Journal of Kunming Medical University, 2024, 45(4): 74-80. doi: 10.12259/j.issn.2095-610X.S20240411

Citation:

Fen TENG, Bo TIAN, Chongxi LI, Yongmei JIN, Haiyun CHEN, Jun LIU. Real-World Clinical Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide （BIC/FTC/TAF） Single-Tablet Regimen[J]. Journal of Kunming Medical University, 2024, 45(4): 74-80. doi: 10.12259/j.issn.2095-610X.S20240411

PDF( 1017 KB)

Real-World Clinical Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide （BIC/FTC/TAF） Single-Tablet Regimen

doi: 10.12259/j.issn.2095-610X.S20240411

1.
School of Public Health，Dali University，Dali Yunan 671000
2.
Dept.of Infectious Disease，Kunming Third People’s Hospital，Kunming Yunnan 650041，China

Received Date: 2023-08-28
Available Online: 2023-12-21
Publish Date: 2024-04-29

Abstract

Abstract

Objective To analyze the efficacy and safety of the three-in-one single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide（BIC/FTC/TAF） in AIDS patients. Methods Newly treated patients who received a single tablet combination（BIC/FTC/TAF） between February 1, 2022 and June 1, 2022（the initial treatment group） and those who underwent treatment（the treated group） were included. The virological, immunological and biochemical indexes were statistically analyzed by means of prospective observational study. Results 249 patients were included at baseline , with 220 in the treated group and 29 in the newly treated group. At 48 weeks, the analysis showed that the virus suppression rate was 93.10% for the newly treated group and 98.55% for the treated group. Compared to the baseline, both groups showed increased CD4⁺ T lymphocyte counts and CD4⁺/CD8⁺ T cell ratios after 48 weeks of treatment（P < 0.001）. There were also significant increases in blood triglycerides, total cholesterol, total bilirubin, and blood creatinine compared to the baseline（P < 0.05）. Aspartate aminotransferase and alanine aminotransferase decreased compared to the baseline, with all differences being statistically significant except for alanine aminotransferase in the newly treated group（P > 0.05）. Additionally, the estimated glomerular filtration rate based on blood creatinine improved in the newly treated group compared to the baseline（P < 0.001）, while there were no significant changes in the treated group. Conclusion BIC/FTC/TAF can effectively inhibit virus replication, improve the immune function of patients, and has good safety. Bic /FTC/TAF can be one of the preferred treatment options for some specific clinical populations.
- HIV/AIDS,
- BIC/FTC/TAF,
- Real l-world,
- Efficacy,
- Safety

FullText(HTML)

References(25)

References

[1]	谭清,周仲辉,严冬梅,等. 成年人类免疫缺陷病毒感染者/艾滋病患者长期抗病毒治疗后免疫功能重建分析[J]. 中国全科医学,2020,23(23):2918-2922.
[2]	张福杰,赵燕,马烨,等. 中国免费艾滋病抗病毒治疗进展与成就[J]. 中国艾滋病性病,2022,28(1):6-9.
[3]	肖然,付强,杜小莉,等. 多替拉韦用于艾滋病治疗的临床应用[J]. 中国药学杂志,2023,58(6):544-550.
[4]	Liu P,Tang Z,Lan G,et al. Early antiretroviral therapy on reducing HIV transmission in China: Strengths,weaknesses and next focus of the program[J]. Sci Rep,2018,8(1):3431. doi: 10.1038/s41598-018-21791-2
[5]	卢洪洲,沈银忠. 整合酶抑制剂临床应用专家共识[J]. 上海预防医学,2018,30(10):836-843.
[6]	Rolle C P,Nguyen V,Patel K,et al. Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV[J]. Medicine (Baltimore),2021,100(38):e27330.
[7]	Sandulescu O,Irimia M,Benea O E,et al. Treatment initiation or switch to BIC/FTC/TAF - real-world safety and efficacy data from two HIV centers in Romania[J]. Germs,2021,11(4):512-522. doi: 10.18683/germs.2021.1286
[8]	Tabak F,Zerdali E,Altuntas O,et al. Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: Real-world data[J]. Int J STD AIDS,2021,32(6):562-569. doi: 10.1177/0956462420983692
[9]	中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 协和医学杂志,2022,13(2):203-226.
[10]	Saa G M S,Gandhi R T,Hoy J F,et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society-USA panel[J]. JAMA,2020,324(16):1651-1669. doi: 10.1001/jama.2020.17025
[11]	Arribas J, Marzolini C, Mallon P, et al. European AIDS Clinical Society Guidelines, （version 10.1） [EB/OL]. [2021-02-20].https://www.eacsociety.org/files/guidelines-10.1-30032021-1.pdf.
[12]	D H H S. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV[EB/OL]. [2021-03-12].https://aidsinfo.nih.gov/guidelines on 12/28/2019.
[13]	Gallant J,Lazzarin A,Mills A,et al. Bictegravir,emtricitabine,and tenofovir alafenamide versus dolutegravir,abacavir,and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): A double-blind,multicentre,phase 3,randomised controlled non-inferiority trial[J]. Lancet,2017,390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7
[14]	Sax P E,Pozniak A,Montes M L,et al. Coformulated bictegravir,emtricitabine,and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide,for initial treatment of HIV-1 infection (GS-US-380-1490): A randomised,double-blind,multicentre,phase 3,non-inferiority trial[J]. Lancet,2017,390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1
[15]	Molina J M,Ward D,Brar I,et al. Switching to fixed-dose bictegravir,emtricitabine,and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised,double-blind,multicentre,active-controlled,phase 3,non-inferiority trial[J]. Lancet HIV,2018,5(7):e357-e365. doi: 10.1016/S2352-3018(18)30092-4
[16]	Daar E S,DeJesus E,Ruane P,et al. Efficacy and safety of switching to fixed-dose bictegravir,emtricitabine,and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised,open-label,multicentre,phase 3,non-inferiority trial[J]. Lancet HIV,2018,5(7):e347-e356. doi: 10.1016/S2352-3018(18)30091-2
[17]	Lanoy E,May M,Mocroft A,et al. Prognosis of patients treated with cART from 36 months after initiation,according to current and previous CD4 cell count and plasma HIV-1 RNA measurements[J]. AIDS,2009,23(16):2199-2208. doi: 10.1097/QAD.0b013e3283305a00
[18]	荆凡辉,吕玮,李太生. HIV感染者免疫功能重建新视角: CD4/CD8比值[J]. 中国艾滋病性病,2018,24(6):643-646.
[19]	Serrano-Villar S,Martínez-Sanz J,Ron R,et al. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: A prospective multicentre cohort study[J]. Lancet HIV,2020,7(8):e565-e573. doi: 10.1016/S2352-3018(20)30202-2
[20]	陈丽文,高文军,祝达,等. TDF转换为TAF治疗病毒学应答后CHB的疗效和安全性研究[J]. 数理医药学杂志,2021,34(3):384-387.
[21]	Milinkovic A,Berger F,Arenas-Pinto A,et al. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back[J]. AIDS,2019,33(15):2387-2391. doi: 10.1097/QAD.0000000000002350
[22]	Suzuki K,Suda G,Yamamoto Y,et al. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B[J]. PLoS One,2022,17(1):e261760.
[23]	Pottel H,Bjork J,Courbebaisse M,et al. Development and validation of a modified full age spectrum creatinine-based equation to estimate glomerular filtration rate: A cross-sectional analysis of pooled data[J]. Ann Intern Med,2021,174(2):183-191. doi: 10.7326/M20-4366
[24]	Hines D M,Ding Y,Wade R L,et al. Treatment adherence and persistence among HIV-1 patients newly starting treatment[J]. Patient Prefer Adherence,2019,13:1927-1939. doi: 10.2147/PPA.S207908
[25]	Bangsberg D R,Ragland K,Monk A,et al. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people[J]. AIDS,2010,24(18):2835-2840. doi: 10.1097/QAD.0b013e328340a209

Relative Articles(20)

Relative Articles

[1]	Guonian HE, Yongmei JIN, Bo TIAN, Shoukun CHEN, Nihong LU, Jun LIU. Survey on Mental Disorders in HIV/AIDS Patients with End-stage Renal Disease on Hemodialysis. Journal of Kunming Medical University, 2026, 47(1): 1-9.
[2]	Liyuan YUN, Junfeng WANG, Ning GUO, Ruimei DING, Haipeng LI, Xueping ZHANG. Analysis of the Efficacy and Safety of GM1 Injection Combined with Batroxobin in the Treatment of Sudden Deafness Patients. Journal of Kunming Medical University, 2024, 45(6): 140-144. doi: 10.12259/j.issn.2095-610X.S20240619
[3]	Jianmei LI, Yanling JIN. Efficacy and Safety of Bortezomib，Lenalidomide Combined with Dexamethasone in the Treatment of Multiple Myeloma. Journal of Kunming Medical University, 2023, 44(6): 120-125. doi: 10.12259/j.issn.2095-610X.S20230610
[4]	Xiaohua LU, Hongxin YUAN. The Analysis of the Correlation between BTLA，CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer. Journal of Kunming Medical University, 2023, 44(9): 126-135. doi: 10.12259/j.issn.2095-610X.S20230927
[5]	Xing LIU, Chunhong YU, Weixian LI, Bing OUYANG, Lingjun SHEN. A Randomized Controlled Study on the Treatment of Multidrugresistant Tuberculosis with a Regimen Containing Bedaquiline Fumarate Tablets. Journal of Kunming Medical University, 2023, 44(12): 150-158. doi: 10.12259/j.issn.2095-610X.S20231224
[6]	Shuishui PAN, Jinsong BAI, Chongxi LI, Zhiqiong AI, Bo TIAN, Changlei MU, Yihan LIU, Jun LIU. Influencing Factors of Echocardiographic Abnormalities in HIV/AIDS Patients. Journal of Kunming Medical University, 2023, 44(4): 148-153. doi: 10.12259/j.issn.2095-610X.S20230422
[7]	Shuishui PAN, Jinsong BAI, Chongxi LI, Haiyun CHEN, Jun LIU, Zhiqiong AI. Characterization of Cardiac Color Ultrasonography and Carotid Ultrasonography in HIV/AIDS Patients in Different Age Groups. Journal of Kunming Medical University, 2022, 43(10): 66-73. doi: 10.12259/j.issn.2095-610X.S20221016
[8]	Yanwen XU, Xin WANG, Hua JIANG, Chenchen LIANG, Li LIU, Shenghao LI, Jianpeng GAO. Efficacy and Safety of Sofosbuvir-based Drugs for the Treatment of Patients with Chronic Hepatitis C Genotype 3： A Single Centre Real-world Retrospective Analysis. Journal of Kunming Medical University, 2022, 43(11): 124-129. doi: 10.12259/j.issn.2095-610X.S20221115
[9]	Zhi-rong ZHAO, Hai-wen LI, Ni-hong LU, Ling SHEN, Xiao-fei LI, Yong-rui YANG. A Clinical Study on the Use of Propofol Tenofovir in the Treatment of Chronic Hepatitis B. Journal of Kunming Medical University, 2021, 42(1): 89-93. doi: 10.12259/j.issn.2095-610X.S20210141
[10]	Bo TIAN, Jun LIU, Li-hua ZHANG, Rong HE, Shan-qun GU, Chong-xi LI. Disease Distribution Pattern Among HIV/AIDS Inpatients in Kunming from 2012 to 2020. Journal of Kunming Medical University, 2021, 42(8): 152-157. doi: 10.12259/j.issn.2095-610X.S20210827
[11]	Tian Bo , He Li Ping , Liu Jun , Li Zhong Xi , Bai Jing Song , Gu Shan Qun . . Journal of Kunming Medical University, 2020, 41(02): 163-167.
[12]	Jin-jiang YANG, Liu-jiang LI, Shi-jun SHEN, Zhao-xiang LI, Yong YANG, Guo-jian LI. Clinical Trial of Rivaroxaban after Implantation of Stent for Femoral Popliteal Atherosclerosis Occlusion. Journal of Kunming Medical University, 2020, 41(11): 83-87. doi: 10.12259/j.issn.2095-610X.S20201122
[13]	Luo Wei , Wang Shun Jun , Fang Ke Wei , Chen Tao , Chen Rong Qiong , Wang Hui Tao , Yang Bo Wei , Guo Hai Xiang , Zhang Hai Yan , Li Pei , Ke Chang Xing , Liu Jian He . . Journal of Kunming Medical University, 2019, 40(12): 124-129.
[14]	Chang Song Jie . The Clinical Efficacy and Safety of Decreasing Blood Uric Acid by Benzene Bromine Malone in Treatment of Hyperuricemia with Elderly Hypertension and Diabetes Mellitus. Journal of Kunming Medical University,
[15]	Pan Zi Peng . Analysis and Safety Evaluation of the Clinical Efficacy of Laparoscopic Appendectomy for Acute Appendicitis. Journal of Kunming Medical University,
[16]	Zeng Hai Ping . . Journal of Kunming Medical University,
[17]	Yang Yong Rui . . Journal of Kunming Medical University,
[18]	Wang Ji Cai . . Journal of Kunming Medical University,
[19]	Yang Xi Yun . . Journal of Kunming Medical University,
[20]	Wang Ji Cai . . Journal of Kunming Medical University,